WEBULL

Illumina’s AI Genomics Partnership With MyOme Might Change The Case For Investing In Illumina (ILMN)

Simply Wall St · 1d ago
  • Illumina and MyOme recently announced a collaboration and Illumina investment to support MyOme’s Proactive Health Trial, which will test whether combining whole-genome sequencing with AI-integrated risk models improves outcomes and reduces healthcare costs across common, chronic, cancer, and rare diseases.
  • The partnership highlights how Illumina aims to link its population-scale sequencing capabilities with AI-driven, ancestry-relevant risk assessment tools that could influence how preventive care and rare disease diagnostics are delivered and paid for in the US$5.00 trillion US healthcare system.
  • We’ll now examine how Illumina’s push into AI-enabled, whole-genome–based preventive health with MyOme could reshape its longer-term investment narrative.

Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Illumina Investment Narrative Recap

To own Illumina, you need to believe genomic sequencing keeps pushing deeper into clinical and preventive care, offsetting softer research demand, China headwinds, and rising competition. The MyOme collaboration underscores Illumina’s bet on AI-enabled whole genome sequencing in healthcare, but it does not fundamentally change the near term dependence on clinical adoption and reimbursement as the key catalyst, or on research and China weakness as major risks.

The most relevant context for this deal is Illumina’s ongoing collaboration with NVIDIA on multiomic AI tools, which also seeks to turn Illumina’s data scale into differentiated clinical insights. Together with MyOme, it reinforces a broader push to tie Illumina’s sequencing platforms to AI driven applications that may support clinical consumables volumes, while still leaving the business exposed to research funding pressure and intensifying sequencing competition.

Yet investors should also be aware that intensifying competition in high and mid throughput sequencing could...

Read the full narrative on Illumina (it's free!)

Illumina's narrative projects $4.8 billion revenue and $873.5 million earnings by 2028.

Uncover how Illumina's forecasts yield a $119.84 fair value, a 11% downside to its current price.

Exploring Other Perspectives

ILMN 1-Year Stock Price Chart
ILMN 1-Year Stock Price Chart

Four fair value estimates from the Simply Wall St Community span roughly US$102 to US$157 per share, showing how far opinions can spread. When you set that against Illumina’s reliance on continued clinical adoption of sequencing for growth, it underlines why many market participants are weighing both upside from applications like AI enabled preventive health and downside from weaker research and China demand before taking a view on the company’s performance.

Explore 4 other fair value estimates on Illumina - why the stock might be worth 24% less than the current price!

Build Your Own Illumina Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Illumina research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.